Routine employee warrant grant with no immediate trading signal. Monitor upcoming quarterly earnings for commercial progress on Skytrofa and Yorvipath, which are the primary value drivers.
Price Chart
Executive Summary
Ascendis Pharma filed a 6-K reporting the grant of 14,060 warrants to employees at an exercise price of $265.57 per share, with standard time-based vesting (25% after one year, 75% monthly thereafter). The filing also updates the company's Articles of Association to reflect this grant. This is a routine employee compensation event with no material financial impact.
Key Facts
- 14,060 warrants granted to employees on July 14, 2026
- Exercise price of $265.57 per share (closing price on grant date)
- Warrants vest 25% after one year, remaining 75% over 36 months
- After this grant, 1,539,503 shares remain available for future warrant grants
- Articles of Association updated to reflect the grant
Financial Impact
No material financial impact; 14,060 warrants represent a de minimis potential dilution relative to the company's $16.5B market cap
Risk Factors
- Potential future dilution from outstanding warrants (4,773,525 outstanding as of this filing)
- None from this specific filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-304903 |
| Document: d109910d6k.htm | 0001193125-26-304903 |
| Document: 0001193125-26-304903-index-headers.html | 0001193125-26-304903 |
| Document: 0001193125-26-304903-index.html | 0001193125-26-304903 |
| Document: 0001193125-26-304903.txt | 0001193125-26-304903 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access